Prostate cancer early detection
Since the early 1990s when the ACS developed guidelines for the early detection of prostate cancer, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, th...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 语言: | English |
| 出版: |
2007
|
| _version_ | 1826292202733568000 |
|---|---|
| author | Kawachi, M Bahnson, R Barry, M Carroll, P Carter, H Catalona, W Epstein, J Etzioni, R Hemstreet, G Howe, R Kopin, J Lange, P Lilja, H Mohler, J Moul, J Nadler, R Patterson, S Pollack, A Presti, J Stroup, A Urban, D Wake, R Wei, J |
| author_facet | Kawachi, M Bahnson, R Barry, M Carroll, P Carter, H Catalona, W Epstein, J Etzioni, R Hemstreet, G Howe, R Kopin, J Lange, P Lilja, H Mohler, J Moul, J Nadler, R Patterson, S Pollack, A Presti, J Stroup, A Urban, D Wake, R Wei, J |
| author_sort | Kawachi, M |
| collection | OXFORD |
| description | Since the early 1990s when the ACS developed guidelines for the early detection of prostate cancer, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, the NCCN guidelines recommend how individuals and their physicians can use these new methods rationally for the early detection of prostate cancer. These guidelines are not designed to provide an argument for using early detection programs for prostate cancer, but are meant to provide a vehicle with which early detection efforts can be practiced in an evidence-based, systematic fashion in patients who choose to participate in these programs.56 These NCCN guidelines incorporate many new validated findings in addition to the DRE and tPSA test. These new factors include percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical usefulness of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program of early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances. © Journal of the National Comprehensive Cancer Network. |
| first_indexed | 2024-03-07T03:11:03Z |
| format | Journal article |
| id | oxford-uuid:b43779fb-9e0f-43f1-b65c-381758a556d3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:11:03Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:b43779fb-9e0f-43f1-b65c-381758a556d32022-03-27T04:24:35ZProstate cancer early detectionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b43779fb-9e0f-43f1-b65c-381758a556d3EnglishSymplectic Elements at Oxford2007Kawachi, MBahnson, RBarry, MCarroll, PCarter, HCatalona, WEpstein, JEtzioni, RHemstreet, GHowe, RKopin, JLange, PLilja, HMohler, JMoul, JNadler, RPatterson, SPollack, APresti, JStroup, AUrban, DWake, RWei, JSince the early 1990s when the ACS developed guidelines for the early detection of prostate cancer, many variants of the tPSA assay have been introduced to increase the sensitivity of screening programs (cancer detection) while maintaining specificity (elimination of unnecessary biopsies). Again, the NCCN guidelines recommend how individuals and their physicians can use these new methods rationally for the early detection of prostate cancer. These guidelines are not designed to provide an argument for using early detection programs for prostate cancer, but are meant to provide a vehicle with which early detection efforts can be practiced in an evidence-based, systematic fashion in patients who choose to participate in these programs.56 These NCCN guidelines incorporate many new validated findings in addition to the DRE and tPSA test. These new factors include percent fPSA, PSAV, cPSA, biopsy pathology, and TRUS-guided biopsy techniques. The panel will re-examine the clinical usefulness of these new modalities annually, and the guidelines will be modified accordingly. In addition, future iterations of these guidelines may incorporate new serum markers currently undergoing clinical investigation. The goal of the NCCN and this guideline panel in updating these algorithms is to help men and clinicians choose a program of early detection of prostate cancer and make decisions about the need for prostate biopsy. Any clinician who uses these guidelines is expected to exercise independent medical judgment in the context of the individual clinical circumstances to determine each patient's need for prostate biopsy. These guidelines will continue to evolve as the field of prostate cancer advances. © Journal of the National Comprehensive Cancer Network. |
| spellingShingle | Kawachi, M Bahnson, R Barry, M Carroll, P Carter, H Catalona, W Epstein, J Etzioni, R Hemstreet, G Howe, R Kopin, J Lange, P Lilja, H Mohler, J Moul, J Nadler, R Patterson, S Pollack, A Presti, J Stroup, A Urban, D Wake, R Wei, J Prostate cancer early detection |
| title | Prostate cancer early detection |
| title_full | Prostate cancer early detection |
| title_fullStr | Prostate cancer early detection |
| title_full_unstemmed | Prostate cancer early detection |
| title_short | Prostate cancer early detection |
| title_sort | prostate cancer early detection |
| work_keys_str_mv | AT kawachim prostatecancerearlydetection AT bahnsonr prostatecancerearlydetection AT barrym prostatecancerearlydetection AT carrollp prostatecancerearlydetection AT carterh prostatecancerearlydetection AT catalonaw prostatecancerearlydetection AT epsteinj prostatecancerearlydetection AT etzionir prostatecancerearlydetection AT hemstreetg prostatecancerearlydetection AT hower prostatecancerearlydetection AT kopinj prostatecancerearlydetection AT langep prostatecancerearlydetection AT liljah prostatecancerearlydetection AT mohlerj prostatecancerearlydetection AT moulj prostatecancerearlydetection AT nadlerr prostatecancerearlydetection AT pattersons prostatecancerearlydetection AT pollacka prostatecancerearlydetection AT prestij prostatecancerearlydetection AT stroupa prostatecancerearlydetection AT urband prostatecancerearlydetection AT waker prostatecancerearlydetection AT weij prostatecancerearlydetection |